Diagnosis of recurrent or multiphasic ADEM (as per IPMSSG criteria) (Krupp et al. 2013). AND Evidence of deterioration in symptoms. AND Relapse occurs within six months of the last immunoglobulin (Ig) dose. 1Krupp, LB, Tardieu, M, Amato, MP, et al 2013, ‘International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions’, Multiple Sclerosis Journal, vol. 19, pp. 1261–1267. Review Criteria ADEM unresponsive to steroid Response must be demonstrated Monophasic therapy or where steroids are contraindicated. after 6 months treatment for Trial off therapy must be undertaken after 12 months No review is required. Further doses of Ig can treatment. If patients with Recurrent be requested as required for patients with or Multi-phasic ADEM relapse within extended monophasic ADEM. 6 months of ceasing Ig treatment, is defined with requirement Recurrent or multiphasic ADEM unresponsive to for further response at review. steroid therapy or where steroid therapy has become intolerable or is contraindicated, with assessment by a neurologist mandatory. Review Preamble Objective evidence of improvement in relapse rate in comparison to pre-treatment levels is required for reauthorisation. Six-monthly review by a neurologist is required
Diagnosis of recurrent or multiphasic ADEM (as per IPMSSG criteria) (Krupp et al. 2013). AND Evidence of deterioration in symptoms. AND Relapse occurs within six months of the last immunoglobulin (Ig) dose. 1Krupp, LB, Tardieu, M, Amato, MP, et al 2013, ‘International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions’, Multiple Sclerosis Journal, vol. 19, pp. 1261–1267. Review Criteria Monophasic ADEM unresponsive to steroid therapy or where steroids are contraindicated. No review is required. Further doses of Ig can be requested as required for patients with extended monophasic ADEM. Recurrent or multiphasic ADEM unresponsive to steroid therapy or where steroid therapy has become intolerable or is contraindicated, with assessment by a neurologist mandatory. Review Preamble Objective evidence of improvement in relapse rate in comparison to pre-treatment levels is required for reauthorisation. Six-monthly review by a neurologist is required Response must be demonstrated after 6 months treatment for Trial off therapy must be undertaken after 12 months treatment. If patients with Recurrent or Multi-phasic ADEM relapse within 6 months of ceasing Ig treatment, is defined with requirement for further response at review.
acute-disseminated-encephalomyelitis%28adem%29.DOCX